Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes

The aim of this study was to divide the group of triple-negative breast cancer patients with brain metastases into basal-like and non-basal-like biological subtypes in order to compare clinical features and survival rates in those two groups. A comprehensive analysis of 111 consecutive triple-negati...

Full description

Bibliographic Details
Main Authors:	Niwińska, Anna, Olszewski, Wojciech, Murawska, Magdalena, Pogoda, Katarzyna
Format:	Online
Language:	English
Published:	Springer US 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215879/

id	pubmed-3215879
recordtype	oai_dc
spelling	pubmed-32158792011-12-09 Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes Niwińska, Anna Olszewski, Wojciech Murawska, Magdalena Pogoda, Katarzyna Clinical Study – Patient Study The aim of this study was to divide the group of triple-negative breast cancer patients with brain metastases into basal-like and non-basal-like biological subtypes in order to compare clinical features and survival rates in those two groups. A comprehensive analysis of 111 consecutive triple-negative breast cancer patients with brain metastases treated in the years 2003–2009 was performed. In 75 patients, immunohistochemistry was used as a surrogate of microarray in order to evaluate the expression of three basal markers: cytokeratin 5/6 (CK 5/6), EGFR/HER1 and c-KIT. The basal-like (ER/PgR/HER2-negative, CK5/6positive and/or HER1-positive) and non-basal-like (ER/PgR/HER2-negative, CK5/6-negative, HER1-negative) subsets were selected. Clinical features and survivals were compared in both groups. In the group of 111 triple-negative breast cancer patients, median DFS, OS and survival from brain metastases were 20, 29 and 4 months, respectively. In 75 patients who were evaluable for basal markers, median DFS, OS and survival from brain metastases were 18, 26 and 3.2 months, respectively. In the basal-like subtype, the survival rates were 15, 26 and 3 months, respectively, and in the non-basal-like subtypes, they were 20, 30 and 2.8 months, respectively. No statistically significant differences in survivals were detected between the basal-like and non-basal-like biological subtypes. Factors influencing survival from brain metastases were: Karnofsky performance status (KPS), the status of extracranial disease and age. Biological markers differentiating triple-negative group into basal-like and non-basal-like subtype (CK 5/6, HER1, c-KIT) had no influence on survival. In patients with triple-negative breast cancer and brain metastases, well-known clinical, but not molecular, features correlated with survival. Springer US 2011-06-09 2011-12 /pmc/articles/PMC3215879/ /pubmed/21656328 http://dx.doi.org/10.1007/s11060-011-0616-3 Text en © The Author(s) 2011
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Niwińska, Anna Olszewski, Wojciech Murawska, Magdalena Pogoda, Katarzyna
spellingShingle	Niwińska, Anna Olszewski, Wojciech Murawska, Magdalena Pogoda, Katarzyna Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
author_facet	Niwińska, Anna Olszewski, Wojciech Murawska, Magdalena Pogoda, Katarzyna
author_sort	Niwińska, Anna
title	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
title_short	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
title_full	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
title_fullStr	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
title_full_unstemmed	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
title_sort	triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
description	The aim of this study was to divide the group of triple-negative breast cancer patients with brain metastases into basal-like and non-basal-like biological subtypes in order to compare clinical features and survival rates in those two groups. A comprehensive analysis of 111 consecutive triple-negative breast cancer patients with brain metastases treated in the years 2003–2009 was performed. In 75 patients, immunohistochemistry was used as a surrogate of microarray in order to evaluate the expression of three basal markers: cytokeratin 5/6 (CK 5/6), EGFR/HER1 and c-KIT. The basal-like (ER/PgR/HER2-negative, CK5/6positive and/or HER1-positive) and non-basal-like (ER/PgR/HER2-negative, CK5/6-negative, HER1-negative) subsets were selected. Clinical features and survivals were compared in both groups. In the group of 111 triple-negative breast cancer patients, median DFS, OS and survival from brain metastases were 20, 29 and 4 months, respectively. In 75 patients who were evaluable for basal markers, median DFS, OS and survival from brain metastases were 18, 26 and 3.2 months, respectively. In the basal-like subtype, the survival rates were 15, 26 and 3 months, respectively, and in the non-basal-like subtypes, they were 20, 30 and 2.8 months, respectively. No statistically significant differences in survivals were detected between the basal-like and non-basal-like biological subtypes. Factors influencing survival from brain metastases were: Karnofsky performance status (KPS), the status of extracranial disease and age. Biological markers differentiating triple-negative group into basal-like and non-basal-like subtype (CK 5/6, HER1, c-KIT) had no influence on survival. In patients with triple-negative breast cancer and brain metastases, well-known clinical, but not molecular, features correlated with survival.
publisher	Springer US
publishDate	2011
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215879/
_version_	1611487653885116416

Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes

Similar Items